Global Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size, Status and Forecast 2020-2026
Bruton's tyrosine kinase (Btk), a member of the non-receptor tyrosine kinase Tec family, is a key signaling enzyme expressed in all hematopoietic cell types except T lymphocytes and natural killer cells.Btk plays a crucial role in stimulating B cell signaling pathways that connect the cell surface B cell receptor (BCR) to the downstream intracellular response.
The main levels of BTK inhibitor are divided into Irreversible Inhibitor and Reversible Inhibitor according to therapeutic options.
Bruton tyrosine kinase (BTK) is a key kinase in the signaling pathway of B cell antigen receptor (BCR). Since BTK deficiency mainly affects B cells, BTK naturally becomes an attractive therapeutic target in autoimmune diseases and b-cell malignancies.Many companies are beginning to design kinase-selective inhibitors that target the molecular structure and function of BTK.
Irreversible inhibitors, like all ATP competitive reversible inhibitors, are generally able to compete to occupy the atp-kinase binding cavity.In theory, these inhibitors have infinitely strong binding activity and complete blocking of signaling pathways, and their pharmacodynamic properties are basically independent of their pharmacokinetic advantages, thus greatly improving the utilization efficiency of drugs.
Reversible inhibitors, which are characterized by their ability to competitively occupy the Spaces where ATP binds to kinases, then complete the process of binding to and breaking off from the enzyme within 10 to 15 minutes of drug metabolism, thus achieving a balance.Their effect on target proteins is therefore "transient" relative to that of irreversible inhibitors.Its advantage is that it will not cause permanent damage to the target protein, but only temporarily interfere with its physiological state.
In addition to the mainstream Irreversible Inhibitors systems of various manufacturers, each manufacturer also has different models and functions of Reversible inhibitors
The BTK inhibitor originated in America and rose in Europe and Asia-Pacific. The United States currently accounts for 53% of the global BTK inhibitor market. After BTK inhibitor was discovered for the first time In 1993, Beijing Sailintai Medicine, Onepharm/Gliead, Principiabiopharma Bristol-myers Squibb, Merck , Lilly/Hanmi ,Roche, Takeda, Biological Principiabiopharma Eisen, Zhejiang Ming Guide Medicine Science and Technology, Jiangsu Hengrui developed one after another. The BTK inhibitor is used in Non-hodgkin's lymphoma (NHL), Wm. Abc-Dlbcl, MMMCL, Fahrenheit macroglobulinemia, b-cell lymphoma, b-cell lymphoma, Sjogren's Syndrome, Scarring Ulcer Vulva Rheumatoid Arthritis MCL, CLL rheumatoid arthritis autoimmune diseases.
According to 2019 data released by the CAP, the global market for BTK inhibitors is $5.4 billion. Most markets are concentrated in developed countries such as North America and Europe.
In recent years, with the continuous development of biotechnology and drug development in emerging markets, other countries except Europe and the United States are also growing rapidly. The United States became the main market for BTK inhibitor, while the population of the BRIC countries with large populations is also increasing the demand for BTK inhibitor.
Ibrutinib was launched in China in 2017 for the treatment of relapsed refractory CLL/SLL, refractory MCL and WM, and was listed in the national directory of medicare at the end of 2018. It is the only BTK inhibitor sold in China as of September 30, 2019. China is the fastest growing market in this area. Baiji shenzhou has carried out Zanubrutinib and Ibrutinib on the two indications of WM and CLL. In addition to baiji shenzhou, btk-targeted drugs of many domestic pharmaceutical companies, including nuocheng jianhua, hengrui pharmaceutical, zhejiang dawing and Xinovi, have entered the clinical stage and are expected to be launched after 2020.
Osimertinib has greater target inhibition and selectivity than other approved BTK inhibitors.
Reversible Inhibitors price is high, and the number of target customers is small: a set of
Irreversible Inhibitors prices are over five hundred of dollars per 10mg packed , only applicable to research.
Irreversible Inhibitors can be flexibly combined according to specific needs, suitable for most hospitals, biochemical immune cascade running.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bruton's Tyrosine Kinase (Btk) Inhibitors market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bruton's Tyrosine Kinase (Btk) Inhibitors market in terms of revenue.
Players, stakeholders, and other participants in the global Bruton's Tyrosine Kinase (Btk) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Bruton's Tyrosine Kinase (Btk) Inhibitors market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Bruton's Tyrosine Kinase (Btk) Inhibitors market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bruton's Tyrosine Kinase (Btk) Inhibitors market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bruton's Tyrosine Kinase (Btk) Inhibitors market.
The following players are covered in this report:
Johnson & Johnson
AstraZeneca
Roche
Sunesis
Takeda
Bristol- Myers Squibb
Gilead Sciences
AbbVie
Biogen
INNOCARE
ACEA Biosciences
Acerta Pharma
Aptose Biosciences
ArQule
BeiGene
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Hanmi Pharmaceutical
KBP Biosciences
Loxo Oncology
LSK BioPharma
Merck
Ono Pharmaceutical
Pharmacyclics
Principia Biopharma
Tolero
X-Rx
Zhejiang DTRM Biopharma
Bruton's Tyrosine Kinase (Btk) Inhibitors Breakdown Data by Type
IC50<1nM
1nM< IC50<5nM
IC50＞5nM
Bruton's Tyrosine Kinase (Btk) Inhibitors Breakdown Data by Application
Chronic Lymphocytic Leukemia (cll)
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Other Selective B Cell Malignancies
Chronic Graft-versus-host Disease
Other
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Bruton's Tyrosine Kinase (Btk) Inhibitors Revenue
1.4 Market Analysis by Type
1.4.1 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 IC50<1nM
1.4.3 1nM< IC50<5nM
1.4.4 IC50＞5nM
1.5 Market by Application
1.5.1 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Market Share by Application: 2020 VS 2026
1.5.2 Chronic Lymphocytic Leukemia (cll)
1.5.3 Follicular Lymphoma
1.5.4 Mantle Cell Lymphoma
1.5.5 Marginal Zone Lymphoma
1.5.6 Small Lymphocytic Lymphoma
1.5.7 Waldenstrom Macroglobulinemia
1.5.8 Other Selective B Cell Malignancies
1.5.9 Chronic Graft-versus-host Disease
1.5.10 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Bruton's Tyrosine Kinase (Btk) Inhibitors Market Perspective (2015-2026)
2.2 Bruton's Tyrosine Kinase (Btk) Inhibitors Growth Trends by Regions
2.2.1 Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Bruton's Tyrosine Kinase (Btk) Inhibitors Historic Market Share by Regions (2015-2020)
2.2.3 Bruton's Tyrosine Kinase (Btk) Inhibitors Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Bruton's Tyrosine Kinase (Btk) Inhibitors Market Growth Strategy
2.3.6 Primary Interviews with Key Bruton's Tyrosine Kinase (Btk) Inhibitors Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Bruton's Tyrosine Kinase (Btk) Inhibitors Players by Market Size
3.1.1 Global Top Bruton's Tyrosine Kinase (Btk) Inhibitors Players by Revenue (2015-2020)
3.1.2 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Revenue Market Share by Players (2015-2020)
3.1.3 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Market Concentration Ratio
3.2.1 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Bruton's Tyrosine Kinase (Btk) Inhibitors Revenue in 2019
3.3 Bruton's Tyrosine Kinase (Btk) Inhibitors Key Players Head office and Area Served
3.4 Key Players Bruton's Tyrosine Kinase (Btk) Inhibitors Product Solution and Service
3.5 Date of Enter into Bruton's Tyrosine Kinase (Btk) Inhibitors Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Historic Market Size by Type (2015-2020)
4.2 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Forecasted Market Size by Type (2021-2026)
5 Bruton's Tyrosine Kinase (Btk) Inhibitors Breakdown Data by Application (2015-2026)
5.1 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Application (2015-2020)
5.2 Global Bruton's Tyrosine Kinase (Btk) Inhibitors Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size (2015-2020)
6.2 Bruton's Tyrosine Kinase (Btk) Inhibitors Key Players in North America (2019-2020)
6.3 North America Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Type (2015-2020)
6.4 North America Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Application (2015-2020)
7 Europe
7.1 Europe Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size (2015-2020)
7.2 Bruton's Tyrosine Kinase (Btk) Inhibitors Key Players in Europe (2019-2020)
7.3 Europe Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Type (2015-2020)
7.4 Europe Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Application (2015-2020)
8 China
8.1 China Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size (2015-2020)
8.2 Bruton's Tyrosine Kinase (Btk) Inhibitors Key Players in China (2019-2020)
8.3 China Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Type (2015-2020)
8.4 China Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Application (2015-2020)
9 Japan
9.1 Japan Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size (2015-2020)
9.2 Bruton's Tyrosine Kinase (Btk) Inhibitors Key Players in Japan (2019-2020)
9.3 Japan Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Type (2015-2020)
9.4 Japan Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size (2015-2020)
10.2 Bruton's Tyrosine Kinase (Btk) Inhibitors Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Type (2015-2020)
10.4 Southeast Asia Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Application (2015-2020)
11 India
11.1 India Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size (2015-2020)
11.2 Bruton's Tyrosine Kinase (Btk) Inhibitors Key Players in India (2019-2020)
11.3 India Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Type (2015-2020)
11.4 India Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size (2015-2020)
12.2 Bruton's Tyrosine Kinase (Btk) Inhibitors Key Players in Central & South America (2019-2020)
12.3 Central & South America Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Type (2015-2020)
12.4 Central & South America Bruton's Tyrosine Kinase (Btk) Inhibitors Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Johnson & Johnson
13.1.1 Johnson & Johnson Company Details
13.1.2 Johnson & Johnson Business Overview and Its Total Revenue
13.1.3 Johnson & Johnson Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.1.4 Johnson & Johnson Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020))
13.1.5 Johnson & Johnson Recent Development
13.2 AstraZeneca
13.2.1 AstraZeneca Company Details
13.2.2 AstraZeneca Business Overview and Its Total Revenue
13.2.3 AstraZeneca Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.2.4 AstraZeneca Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
13.2.5 AstraZeneca Recent Development
13.3 Roche
13.3.1 Roche Company Details
13.3.2 Roche Business Overview and Its Total Revenue
13.3.3 Roche Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.3.4 Roche Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
13.3.5 Roche Recent Development
13.4 Sunesis
13.4.1 Sunesis Company Details
13.4.2 Sunesis Business Overview and Its Total Revenue
13.4.3 Sunesis Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.4.4 Sunesis Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
13.4.5 Sunesis Recent Development
13.5 Takeda
13.5.1 Takeda Company Details
13.5.2 Takeda Business Overview and Its Total Revenue
13.5.3 Takeda Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.5.4 Takeda Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
13.5.5 Takeda Recent Development
13.6 Bristol- Myers Squibb
13.6.1 Bristol- Myers Squibb Company Details
13.6.2 Bristol- Myers Squibb Business Overview and Its Total Revenue
13.6.3 Bristol- Myers Squibb Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.6.4 Bristol- Myers Squibb Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
13.6.5 Bristol- Myers Squibb Recent Development
13.7 Gilead Sciences
13.7.1 Gilead Sciences Company Details
13.7.2 Gilead Sciences Business Overview and Its Total Revenue
13.7.3 Gilead Sciences Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.7.4 Gilead Sciences Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
13.7.5 Gilead Sciences Recent Development
13.8 AbbVie
13.8.1 AbbVie Company Details
13.8.2 AbbVie Business Overview and Its Total Revenue
13.8.3 AbbVie Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.8.4 AbbVie Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
13.8.5 AbbVie Recent Development
13.9 Biogen
13.9.1 Biogen Company Details
13.9.2 Biogen Business Overview and Its Total Revenue
13.9.3 Biogen Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.9.4 Biogen Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
13.9.5 Biogen Recent Development
13.10 INNOCARE
13.10.1 INNOCARE Company Details
13.10.2 INNOCARE Business Overview and Its Total Revenue
13.10.3 INNOCARE Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
13.10.4 INNOCARE Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
13.10.5 INNOCARE Recent Development
13.11 ACEA Biosciences
10.11.1 ACEA Biosciences Company Details
10.11.2 ACEA Biosciences Business Overview and Its Total Revenue
10.11.3 ACEA Biosciences Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.11.4 ACEA Biosciences Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.11.5 ACEA Biosciences Recent Development
13.12 Acerta Pharma
10.12.1 Acerta Pharma Company Details
10.12.2 Acerta Pharma Business Overview and Its Total Revenue
10.12.3 Acerta Pharma Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.12.4 Acerta Pharma Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.12.5 Acerta Pharma Recent Development
13.13 Aptose Biosciences
10.13.1 Aptose Biosciences Company Details
10.13.2 Aptose Biosciences Business Overview and Its Total Revenue
10.13.3 Aptose Biosciences Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.13.4 Aptose Biosciences Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.13.5 Aptose Biosciences Recent Development
13.14 ArQule
10.14.1 ArQule Company Details
10.14.2 ArQule Business Overview and Its Total Revenue
10.14.3 ArQule Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.14.4 ArQule Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.14.5 ArQule Recent Development
13.15 BeiGene
10.15.1 BeiGene Company Details
10.15.2 BeiGene Business Overview and Its Total Revenue
10.15.3 BeiGene Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.15.4 BeiGene Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.15.5 BeiGene Recent Development
13.16 Carna Biosciences
10.16.1 Carna Biosciences Company Details
10.16.2 Carna Biosciences Business Overview and Its Total Revenue
10.16.3 Carna Biosciences Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.16.4 Carna Biosciences Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.16.5 Carna Biosciences Recent Development
13.17 Celgene Corporation
10.17.1 Celgene Corporation Company Details
10.17.2 Celgene Corporation Business Overview and Its Total Revenue
10.17.3 Celgene Corporation Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.17.4 Celgene Corporation Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.17.5 Celgene Corporation Recent Development
13.18 Eternity Bioscience
10.18.1 Eternity Bioscience Company Details
10.18.2 Eternity Bioscience Business Overview and Its Total Revenue
10.18.3 Eternity Bioscience Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.18.4 Eternity Bioscience Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.18.5 Eternity Bioscience Recent Development
13.19 Hanmi Pharmaceutical
10.19.1 Hanmi Pharmaceutical Company Details
10.19.2 Hanmi Pharmaceutical Business Overview and Its Total Revenue
10.19.3 Hanmi Pharmaceutical Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.19.4 Hanmi Pharmaceutical Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.19.5 Hanmi Pharmaceutical Recent Development
13.20 KBP Biosciences
10.20.1 KBP Biosciences Company Details
10.20.2 KBP Biosciences Business Overview and Its Total Revenue
10.20.3 KBP Biosciences Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.20.4 KBP Biosciences Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.20.5 KBP Biosciences Recent Development
13.21 Loxo Oncology
10.21.1 Loxo Oncology Company Details
10.21.2 Loxo Oncology Business Overview and Its Total Revenue
10.21.3 Loxo Oncology Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.21.4 Loxo Oncology Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.21.5 Loxo Oncology Recent Development
13.22 LSK BioPharma
10.22.1 LSK BioPharma Company Details
10.22.2 LSK BioPharma Business Overview and Its Total Revenue
10.22.3 LSK BioPharma Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.22.4 LSK BioPharma Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.22.5 LSK BioPharma Recent Development
13.23 Merck
10.23.1 Merck Company Details
10.23.2 Merck Business Overview and Its Total Revenue
10.23.3 Merck Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.23.4 Merck Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.23.5 Merck Recent Development
13.24 Ono Pharmaceutical
10.24.1 Ono Pharmaceutical Company Details
10.24.2 Ono Pharmaceutical Business Overview and Its Total Revenue
10.24.3 Ono Pharmaceutical Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.24.4 Ono Pharmaceutical Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.24.5 Ono Pharmaceutical Recent Development
13.25 Pharmacyclics
10.25.1 Pharmacyclics Company Details
10.25.2 Pharmacyclics Business Overview and Its Total Revenue
10.25.3 Pharmacyclics Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.25.4 Pharmacyclics Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.25.5 Pharmacyclics Recent Development
13.26 Principia Biopharma
10.26.1 Principia Biopharma Company Details
10.26.2 Principia Biopharma Business Overview and Its Total Revenue
10.26.3 Principia Biopharma Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.26.4 Principia Biopharma Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.26.5 Principia Biopharma Recent Development
13.27 Tolero
10.27.1 Tolero Company Details
10.27.2 Tolero Business Overview and Its Total Revenue
10.27.3 Tolero Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.27.4 Tolero Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.27.5 Tolero Recent Development
13.28 X-Rx
10.28.1 X-Rx Company Details
10.28.2 X-Rx Business Overview and Its Total Revenue
10.28.3 X-Rx Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.28.4 X-Rx Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.28.5 X-Rx Recent Development
13.29 Zhejiang DTRM Biopharma
10.29.1 Zhejiang DTRM Biopharma Company Details
10.29.2 Zhejiang DTRM Biopharma Business Overview and Its Total Revenue
10.29.3 Zhejiang DTRM Biopharma Bruton's Tyrosine Kinase (Btk) Inhibitors Introduction
10.29.4 Zhejiang DTRM Biopharma Revenue in Bruton's Tyrosine Kinase (Btk) Inhibitors Business (2015-2020)
10.29.5 Zhejiang DTRM Biopharma Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
